Dyadic (NASDAQ: DYAI) Secures $3M Gates Foundation Grant to Advance Global Vaccines & Therapeutics with C1 Fungal Platform - More Stocks Inside

We are pleased to share an exciting update on Dyadic International, Inc. (NASDAQ: DYAI), a company at the forefront of transforming vaccine development through its proprietary C1 filamentous fungal platform. This breakthrough technology is set to revolutionize global health by significantly reducing vaccine development timelines, enhancing production scalability, and sustainably making vaccines available worldwide.

Key Highlights:

- Accelerated Vaccine Production

In a critical step toward addressing one of the most pressing challenges in pandemic preparedness-speed, scalability, and cost-Dyadic's C1 platform is designed to cut vaccine development timelines down to as little as 35 days. Traditional mammalian and insect cell-based methods typically require months to generate stable vaccine components. Dyadic's approach aligns with CEPI's 100 Days Mission, a global initiative to deploy vaccines within three months of identifying a new pandemic threat.

- Strategic Partnership with CEPI and FBS

The Coalition for Epidemic Preparedness Innovations (CEPI) has awarded $4.5 million to the Italian nonprofit Fondazione Biotecnopolo di Siena (FBS) to fast-track vaccine candidates using Dyadic's C1 platform.

"The flexibility, speed, and affordability of this fungal-based approach make it especially valuable in outbreak situations where time is of the essence," said Dr. Raafat Fahim, Interim Executive Director of Manufacturing and Supply Chain at CEPI.

In addition, Dyadic was recently awarded a $3 million grant from the Bill & Melinda Gates Foundation to support the development of low-cost, scalable biologic therapeutics using the C1 platform. This funding reinforces growing global confidence in the technology's potential to deliver more equitable healthcare solutions.

These endorsements from CEPI and the Gates Foundation mark significant validation of the C1 platform's promise to reshape the future of vaccine and therapeutic production.

- Scientific and Economic Advantages

In the proof-of-concept phase, researchers will produce a SARS-CoV-2 spike protein using both Dyadic's C1 platform and mammalian cell lines to compare structure and immunogenicity. Early findings indicate that C1-produced proteins match quality standards while being produced faster and more cost-effectively.

Unlike mRNA vaccines, which require extreme cold chain logistics, Dyadic's protein-based vaccines are easier to store and distribute, particularly in low- and middle-income countries, making global access more achievable.

- Global Health Impact and Investment Rationale

Dyadic's C1 platform has the potential to democratize vaccine production, enabling regional manufacturing in areas with limited infrastructure.

"There's an urgent need for platforms that can deliver billions of affordable vaccine doses quickly," emphasized Prof. Rino Rappuoli, Scientific Director at FBS.

CEPI's Dr. Fahim echoed this sentiment, underscoring the technology's relevance for ensuring equitable responses to future global outbreaks.

- Diverse Market Opportunities Beyond Human Health

Beyond vaccines and monoclonal antibodies, the C1 platform also enables applications in diagnostics, therapeutic proteins, and veterinary health. Its adaptability opens up new revenue streams in companion animal care, livestock health, and other biotech sectors, offering Dyadic a unique advantage through market diversification.

Why Invest in Dyadic International?

* Disruptive Technology: Dyadic's C1 platform significantly reduces vaccine production time, lowers costs, and broadens access to life-saving biologics.
* Strategic Partnerships: Backing from CEPI, the Gates Foundation, and FBS positions Dyadic as a pivotal figure in next-generation vaccine development.
* Expanding Market Demand: As the global community readies for future pandemics, scalable and affordable production platforms like C1 will be essential.
* Robust Funding: Recent combined support totaling $7.5 million from CEPI and the Gates Foundation showcases strong confidence in Dyadic's platform and vision.

Dyadic International (NASDAQ: DYAI) is not just participating in the vaccine revolution-it is driving it. With a visionary technology, high-impact global partnerships, and expanding applicability across human and animal health, Dyadic offers a compelling opportunity for forward-looking investors. As the world moves toward proactive pandemic preparedness, Dyadic is uniquely positioned to deliver faster, more affordable, and globally accessible biologics. For additional information or to schedule a conversation with our analyst team, please don't hesitate to reach out.

- Companies Reporting Earnings This Week to Watch

Dyadic International (NASDAQ: DYAI) will be releasing earnings this week alongside a diverse group of notable companies, including Lululemon Inc. (NASDAQ: LULU), Chewy Inc. (NYSE: CHWY), Dollar Tree Inc. (NASDAQ: DLTR), GameStop Corp. (NYSE: GME), Canadian Solar Inc. (NASDAQ: CSIQ), and Intuitive Machines Inc. (NASDAQ: LUNR), among others. Investors will be closely watching Dyadic's update for insights into its progress on the C1 gene expression platform, recent $3 million grant from the Gates Foundation, and developments in its CEPI-backed vaccine initiatives, which could signal broader momentum in biotech innovation and global health preparedness.

Disclaimers: The Private Securities Litigation Reform Act of 1995 provides investors with a safe harbor with regard to forward-looking statements. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, assumptions, objectives, goals, and assumptions about future events or performance are not statements of historical fact and may be forward looking statements. Forward looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties that could cause actual results or events to differ materially from those presently anticipated. Forward looking statements in this action may be identified through use of words such as projects, foresee, expects, will, anticipates, estimates, believes, understands, or that by statements, indicating certain actions & quotes; may, could or might occur Understand there is no guarantee past performance is indicative of future results. Investing in micro-cap or growth securities is highly speculative and carries an extremely high degree of risk. It is possible that an investor's investment may be lost or due to the speculative nature of the companies profiled. TheStreetReports (TSR) is responsible for the production and distribution of this content."TSR" is not operated by a licensed broker, a dealer, or a registered investment advisor. It should be expressly understood that under no circumstances does any information published herein represent a recommendation to buy or sell a security. "TSR" authors, contributors, or its agents, may be compensated for preparing research, video graphics, podcasts and editorial content. "TSR" has not been compensated to produce content related to "Any Companies" appearing herein. As part of that content, readers, subscribers, and everyone viewing this content are expected to read the full disclaimer in our website.

Media Contact
Company Name: The Street Reports
Contact Person: Editor
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=dyadic-nasdaq-dyai-secures-3m-gates-foundation-grant-to-advance-global-vaccines-therapeutics-with-c1-fungal-platform-more-stocks-inside]
Country: United States
Website: http://www.thestreetreports.com

Legal Disclaimer: Information contained on this page is provided by an independent third-party content provider. ABNewswire makes no warranties or responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you are affiliated with this article or have any complaints or copyright issues related to this article and would like it to be removed, please contact retract@swscontact.com



This release was published on openPR.